Drugs / CDX-6114
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04256655 | Dec 2020 → Dec 2021 | phenylketonuria | Nestlé | Withdrawn | No outcome recorded |
| Phase 1 | NCT04085666 | Jun 2019 → Jun 2020 | phenylketonuria | Nestlé | Completed | No outcome recorded |
| Phase 1 | NCT03797664 | Dec 2018 → Apr 2019 | — | Codexis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03577886 | Jul → Aug 2018 | — | Codexis Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-11-08 | Codexis Inc. | Results Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114 codexis.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-02-14 | Codexis Inc. | Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria codexis.com ↗ |
| 2018-11-08 | Codexis Inc. | Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114 codexis.com ↗ |
| 2018-07-09 | Codexis Inc. | Codexis Doses First Subjects in Phase 1a Trial of CDX-6114 codexis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-6114 | “CDX-6114 for oral administration is formulated in phosphate buffer” NCT04085666 ↗5“Drug: CDX 6114 CDX-6114 for oral administration” NCT04256655 ↗ “Drug: CDX 6114 CDX-6114 for oral administration” NCT04256655 ↗ |
| Route | Oral | “single, oral dose solution” NCT03577886 ↗ |